Search Stock News and Analysis

Clovis Oncology Call Volume Spikes After Downgrade

https://www.schaeffersresearch.com/content/options/2019/09/24/clovis-oncology-call-volume-spikes-after-downgrade

9/24/2019 2:08 PM

SVB Leerink downgraded Clovis Oncology Inc (NASDAQ:CLVS) stock to "market perform" from "outperform," and slashed its price target by $12 to $10. The analyst in coverage called CLVS' licensing deal w...

2 Drug Stocks Dinged by Goldman Downgrades

https://www.schaeffersresearch.com/content/analysis/2019/05/29/2-drug-stocks-dinged-by-goldman-downgrades

5/29/2019 12:56 PM

This morning, Goldman Sachs weighed in on two pharma stocks, downgrading Clovis Oncology Inc (NASDAQ:CLVS) and Esperion Therapeutics Inc (NASDAQ:ESPR) to "sell." Regarding the former, Goldman believes...

Analysts, Options Traders Swarm Sinking CLVS Stock

https://www.schaeffersresearch.com/content/options/2019/04/15/analysts-options-traders-swarm-sinking-clvs-stock

4/15/2019 12:36 PM

Clovis Oncology Inc (NASDAQ:CLVS) late Friday said it was discontinuing a mid-stage trial of its lead cancer drug, rucaparib, in bladder cancer patients following the recommendation of an independent ...

Short Covering Detected on Surging Cancer Stock

https://www.schaeffersresearch.com/content/news/2019/03/04/short-covering-detected-on-surging-cancer-stock

3/4/2019 9:30 AM

The shares of Clovis Oncology Inc (NASDAQ:CLVS) are up 1.3% in electronic trading, on news the pharmaceutical firm's ovarian cancer treatment, rucaparib, is now available in Germany for women with re...

History Says Pump the Brakes on a Clovis Oncology Stock Rally

https://www.schaeffersresearch.com/content/analysis/2019/01/08/history-says-pump-the-brakes-on-a-clovis-oncology-stock-rally

1/8/2019 12:12 PM

Yesterday, Clovis Oncology Inc (NASDAQ:CLVS) surged more than 18%, after better-than-expected sales numbers for its cancer drug Rubraca, as well as a bull note from Leerink. However, the good times f...

PEOPLE ALSO SEARCH FOR